RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $73
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $61 to $73.
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $61 to $73.